Cargando…

Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan

OBJECTIVES: The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for ga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karasawa, Yusuke, Kamae, Isao, Nozawa, Kazutaka, Zeniya, Shigeki, Murata, Tatsunori, Soen, Satoshi, Sakamoto, Choitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259992/ https://www.ncbi.nlm.nih.gov/pubmed/34228745 http://dx.doi.org/10.1371/journal.pone.0253547

Ejemplares similares

A Cost-Effectiveness Analysis Of Pregabalin For The Treatment Of Patients With Chronic Cervical Pain With A Neuropathic Component In Japan
por: Akazawa, Manabu, et al.
Publicado: (2019)

Direct and Indirect Pathways for Health-Related Quality of Life Change from Pain Improvement in Neuropathic Pain Patients with Spine Diseases: Path Analysis with Structural Equation Modeling Using Non-Interventional Study Results of Pregabalin
por: Taguchi, Toshihiko, et al.
Publicado: (2021)

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018)

Dietary therapy for patients with chronic pancreatitis in Japan: a cross-sectional online survey of physicians and registered dietitians
por: Hasebe, Yuko, et al.
Publicado: (2023)

Brand and generic medications: Are they interchangeable?
por: Al-Jazairi, Abdulrazaq S., et al.
Publicado: (2008)

Prescription writing: Generic or brand?
por: Andrade, Chittaranjan, et al.
Publicado: (2017)

Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023)

Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization
por: Alderfer, Justine, et al.
Publicado: (2022)

Barriers to healthcare access in patients with chronic pain or potential migraine in Japan: a cross-sectional internet survey
por: Karasawa, Yusuke, et al.
Publicado: (2023)

The Use of a Network Analysis to Identify Associations and Temporal Patterns Among Non-communicable Diseases in Japan Based on a Large Medical Claims Database
por: Higa, Shingo, et al.
Publicado: (2022)

The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study
por: Murata, Kyoko, et al.
Publicado: (2015)

Safety and efficacy of generic drugs with respect to brand formulation
por: Gallelli, Luca, et al.
Publicado: (2013)

Evaluation of Physical Properties of Generic and Branded Travoprost Formulations
por: Wadhwani, Meenakshi, et al.
Publicado: (2016)

U.S. cannabis laws projected to cost generic and brand pharmaceutical firms billions
por: Bednarek, Ziemowit, et al.
Publicado: (2022)

Efficacy of Combination Therapy with Pregabalin in Neuropathic Pain: A Preclinical Study in the Rat L5 Spinal Nerve Ligation Model
por: Nozawa, Kazutaka, et al.
Publicado: (2022)

Comparison of Generic Drug Reviews for Marketing Authorization between Japan and Canada
por: Kuribayashi, Ryosuke, et al.
Publicado: (2017)

North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
por: Malvankar-Mehta, Monali S, et al.
Publicado: (2019)

Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange
por: Singh, A. K., et al.
Publicado: (2011)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Generic versus brand-name drugs used in cardiovascular diseases
por: Manzoli, Lamberto, et al.
Publicado: (2015)

Assessment of the equivalence of a generic to a branded femoral stem
por: Hothi, H., et al.
Publicado: (2017)

Potential Clinical and Economic Impact of Switching Branded Medications to Generics
por: Straka, Robert J., et al.
Publicado: (2017)

Bioequivalence of generic and branded amoxicillin capsules in healthy human volunteers
por: Pathak, Priyanka, et al.
Publicado: (2017)

HPLC-Based Analysis of Impurities in Sapropterin Branded and Generic Tablets
por: Scudellaro, Emanuela, et al.
Publicado: (2020)

Generics versus brand-named drugs for glaucoma: the debate continues
por: Bhartiya, Shibal, et al.
Publicado: (2020)

Pharmacist Intervention in Safe and Effective Conversion of Brand to Generic Drugs
por: Summers, Kent H.
Publicado: (2005)

A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India
por: Singal, G.L., et al.
Publicado: (2011)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)

Analyzing generic and branded substitution patterns in the Netherlands using prescription data
por: Pechlivanoglou, Petros, et al.
Publicado: (2011)

Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
por: Olszynski, Wojciech P., et al.
Publicado: (2014)

Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations
por: Zhao, Xiao-Ying, et al.
Publicado: (2013)

Recurrence of atrial fibrillation after switching from brand to generic atenolol
por: Gallelli, Luca, et al.
Publicado: (2015)

Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
por: Bosak, Magdalena, et al.
Publicado: (2017)

Elemental impurities analysis in name-brand and generic omeprazole drug samples
por: Pinheiro, Fernanda C., et al.
Publicado: (2020)

Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
por: Yang, Ping, et al.
Publicado: (2021)

Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study
por: George, Thomas, et al.
Publicado: (2021)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
por: Ochi, Nobuaki, et al.
Publicado: (2014)

Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China
por: Toy, Mehlika, et al.
Publicado: (2015)

Healthcare Databases in Thailand and Japan: Potential Sources for Health Technology Assessment Research
por: Saokaew, Surasak, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b4028f84otfq89pelm50gdm091